Clear coverage of hospitals, insurance, pharma, and Washington.
7 stories tracked
Substantial premium hikes threaten to increase out-of-pocket volatility for fixed-income seniors and could drive significant plan churn, directly impacting market share for Part D insurers.
Greater insight into PBM revenue streams and rebate arrangements will give employer plan sponsors critical leverage to negotiate pharmacy contracts and satisfy their federal fiduciary obligations.
Aggressive state-level enforcement could dismantle drugmakers' data mandates, lowering compliance barriers for 340B covered entities while exposing pharmaceutical companies to state legal and regulatory liabilities.
The shutdown poses a critical setback for the biopharma sector's high-profile push to repurpose oncology cell therapies for autoimmune diseases, likely prompting intensified regulatory scrutiny and clinical protocol reassessments across peer pipelines.
Clarifying the regulatory framework for customized therapies reduces development uncertainty for biopharma companies, paving the way for scalable investment in ultra-rare, individualized genetic medicines.
A rising profile for Kennedy's MAHA agenda could pressure federal regulators to overhaul food and drug oversight, while impending outbound investment rules risk disrupting cross-border biotech financing and drug development pipelines.
Restricting new brokers could constrain consumer access to enrollment assistance and disrupt health plans that rely heavily on third-party distribution to drive ACA marketplace enrollment. The escalating litigation also injects regulatory uncertainty into payers' long-term commercial growth strategies for the 2027 plan year.